Literature DB >> 8270935

Seizures due to multiple sclerosis: seven patients with MRI correlations.

A J Thompson1, A G Kermode, I F Moseley, D G MacManus, W I McDonald.   

Abstract

The MRI data of seven patients with clinically definite multiple sclerosis who developed epileptic seizures are presented. Six of these cases demonstrated new or enhancing lesions. Cerebral biopsy in one of these lesions confirmed inflammation with myelin breakdown products. Lesions implicated in the causation of seizures involved the cortex or subcortical area. In one patient, a new lesion was associated with EEG abnormalities which resolved as the lesion reduced in size. In three patients epileptic activity was the only clinical manifestation of disease. Large, unresolving lesions tended to be associated with continuing seizures.

Entities:  

Mesh:

Year:  1993        PMID: 8270935      PMCID: PMC1015382          DOI: 10.1136/jnnp.56.12.1317

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

1.  Epilepsy and disseminated sclerosis.

Authors:  W B MATTHEWS
Journal:  Q J Med       Date:  1962-04

2.  Focal sensory-motor seizures of spinal origin.

Authors:  K A Ekbom; C E Westerberg; P O Osterman
Journal:  Lancet       Date:  1968-01-13       Impact factor: 79.321

3.  Clinically unsuspected cerebral infarction revealed by computed tomography scanning in late onset epilepsy.

Authors:  R C Roberts; S D Shorvon; T C Cox; R W Gilliatt
Journal:  Epilepsia       Date:  1988 Mar-Apr       Impact factor: 5.864

4.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

5.  Racial modification of clinical picture of multiple sclerosis: comparison between British and Japanese patients.

Authors:  H Shibasaki; W I McDonald; Y Kuroiwa
Journal:  J Neurol Sci       Date:  1981-02       Impact factor: 3.181

6.  Prevalence and prognosis of epilepsy in patients with multiple sclerosis.

Authors:  E Kinnunen; J Wikström
Journal:  Epilepsia       Date:  1986 Nov-Dec       Impact factor: 5.864

7.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

8.  The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study.

Authors:  I E Ormerod; D H Miller; W I McDonald; E P du Boulay; P Rudge; B E Kendall; I F Moseley; G Johnson; P S Tofts; A M Halliday
Journal:  Brain       Date:  1987-12       Impact factor: 13.501

9.  Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement.

Authors:  A G Kermode; P S Tofts; A J Thompson; D G MacManus; P Rudge; B E Kendall; D P Kingsley; I F Moseley; E P du Boulay; W I McDonald
Journal:  Neurology       Date:  1990-02       Impact factor: 9.910

10.  Multiple sclerosis with clinical and radiological features of cerebral tumour.

Authors:  H J Sagar; C P Warlow; P W Sheldon; M M Esiri
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-09       Impact factor: 10.154

View more
  10 in total

Review 1.  Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and management.

Authors:  Brendan J Kelley; Moses Rodriguez
Journal:  CNS Drugs       Date:  2009-10       Impact factor: 5.749

Review 2.  Multiple sclerosis: symptomatic treatment.

Authors:  A J Thompson
Journal:  J Neurol       Date:  1996-08       Impact factor: 4.849

3.  Electroencephalographic evidence of gray matter lesions among multiple sclerosis patients: A case-control study.

Authors:  Ahmed Abduljawad Salim; Safaa Hussain Ali; Ansam Munadel Hussain; Wisam Nabeel Ibrahim
Journal:  Medicine (Baltimore)       Date:  2021-08-20       Impact factor: 1.817

4.  Extensive cortical inflammation is associated with epilepsy in multiple sclerosis.

Authors:  Massimiliano Calabrese; Nicola De Stefano; Matteo Atzori; Valentina Bernardi; Irene Mattisi; Luigi Barachino; Luciano Rinaldi; Aldo Morra; Matthew M J McAuliffe; Paola Perini; Leontino Battistin; Paolo Gallo
Journal:  J Neurol       Date:  2008-01-31       Impact factor: 4.849

Review 5.  Paediatric clinically isolated syndromes: report of seven cases, differential diagnosis and literature review.

Authors:  Chiara Trabatti; Thomas Foiadelli; Maria Valentina Spartà; Chiara Gagliardone; Berardo Rinaldi; Maria Delmonte; Alessandro Lozza; Salvatore Savasta
Journal:  Childs Nerv Syst       Date:  2015-11-19       Impact factor: 1.475

Review 6.  Prevalence of Seizure/Epilepsy in Patients with Multiple Sclerosis: A Systematic Review and Meta-Analysis.

Authors:  Omid Mirmosayyeb; Vahid Shaygannejad; Nasim Nehzat; Aida Mohammadi; Mahsa Ghajarzadeh
Journal:  Int J Prev Med       Date:  2021-02-24

7.  Temporal lobe cortical pathology and inhibitory GABA interneuron cell loss are associated with seizures in multiple sclerosis.

Authors:  Richard Nicholas; Roberta Magliozzi; Graham Campbell; Don Mahad; Richard Reynolds
Journal:  Mult Scler       Date:  2015-04-28       Impact factor: 6.312

8.  Seizure characteristics in multiple sclerosis patients.

Authors:  Vahid Shaygannejad; Fereshteh Ashtari; Mohammad Zare; Majid Ghasemi; Rasul Norouzi; Helia Maghzi
Journal:  J Res Med Sci       Date:  2013-03       Impact factor: 1.852

9.  Seizure in Iranian patients with multiple sclerosis.

Authors:  Mohammad Zare; Rasul Norouzi; Vahid Shayegannejad; Fereshteh Ashtari; Majid Ghasemi; Hemaseh Tavahen; Ali Masaeli
Journal:  J Res Med Sci       Date:  2013-07       Impact factor: 1.852

Review 10.  A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications.

Authors:  Larissa Hauer; Julian Perneczky; Johann Sellner
Journal:  J Neurol       Date:  2020-07-27       Impact factor: 4.849

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.